Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS

Sponsor

Masonic Cancer Center, University of Minnesota (Other)

Overall Status

Active, not recruiting

CT.gov ID

NCT04055844

Collaborator

Incyte Corporation (Industry)

Enrollment

Locations

Arm

58.5

Anticipated Duration (Months)

4.7

Patients Per Site

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a multi-center, single-arm, open-label, phase II trial for the frontline treatment of relapsed AML or MDS following allo-HCT. Eligible subjects will receive up to 4 cycles of combined modality treatment. The number of cycles depends on response, toxicity, and the remaining cell dose.

Condition or Disease	Intervention/Treatment	Phase
Acute Myeloid Leukemia Myeloid and Monocytic Leukemia Myelodysplastic Syndromes	Drug: Decitabine Drug: Ruxolitinib Drug: Donor Lymphocyte Infusion (DLI)	Phase 2

Study Design

Study Type:

Interventional

Actual Enrollment :

14 participants

Allocation:

N/A

Intervention Model:

Sequential Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Multi-Center Phase 2 Study of Combined Modality Treatment With Ruxolitinib, Decitabine, and Donor Lymphocyte Infusion for Post-Transplant Relapse of AML or MDS

Actual Study Start Date :

Feb 17, 2020

Anticipated Primary Completion Date :

Jul 1, 2022

Anticipated Study Completion Date :

Jan 1, 2025

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Decitabine + Ruxolitinib + DLI Eligible subjects will receive up to 4 cycles of combined modality treatment. The number of cycles depends on response, toxicity, and the remaining cell dose.	Drug: Decitabine 10 days of decitabine 20 mg/m2 IV daily; or, alternatively, per institution, physician, or patient preference on a 5-2-5 schedule with no weekend infusion. If a CR is achieved after 2 cycles using the 10-day schedule, subsequent cycles will change to a 5-day schedule. Drug: Ruxolitinib Starting with day 1 of cycle 1 and continuing for up to 6 months after the end of the last cycle, patients will receive ruxolitinib 5 mg twice daily orally. Dose may be increased to 10 mg twice daily in cycles 2 through 4 if platelets improve to >100 x 10^9/L. Drug: Donor Lymphocyte Infusion (DLI) DLI from the original donor will be infused within 10 days after the last dose of decitabine in each cycle.

Arm

Intervention/Treatment

Experimental: Decitabine + Ruxolitinib + DLI

Eligible subjects will receive up to 4 cycles of combined modality treatment. The number of cycles depends on response, toxicity, and the remaining cell dose.

Drug: Decitabine

10 days of decitabine 20 mg/m2 IV daily; or, alternatively, per institution, physician, or patient preference on a 5-2-5 schedule with no weekend infusion. If a CR is achieved after 2 cycles using the 10-day schedule, subsequent cycles will change to a 5-day schedule.

Drug: Ruxolitinib

Starting with day 1 of cycle 1 and continuing for up to 6 months after the end of the last cycle, patients will receive ruxolitinib 5 mg twice daily orally. Dose may be increased to 10 mg twice daily in cycles 2 through 4 if platelets improve to >100 x 10^9/L.

Drug: Donor Lymphocyte Infusion (DLI)

DLI from the original donor will be infused within 10 days after the last dose of decitabine in each cycle.

Outcome Measures

Primary Outcome Measures

Efficacy of combined modality treatment (ruxolitinib, decitabine, and DLI) for relapsed AML or MDS post allo-HCT: Rate of Overall Survival (OS) [6 Months]
Rate of Overall Survival (OS)

Secondary Outcome Measures

Efficacy of combined modality treatment (ruxolitinib, decitabine, and DLI) for relapsed AML or MDS post allo-HCT: Rate of Overall Survival (OS) [1 Year]
Rate of Overall Survival (OS)
Grade II-IV acute graft-versus-host disease (aGVHD II-IV) [3 Months]
Cumulative incidence of grade II-IV acute graft-versus-host disease (aGVHD II-IV)
Progression Free Survival (PFS) [6 Months]
Rate of Progression Free Survival (PFS)
Progression Free Survival (PFS) [1 Year]
Rate of Progression Free Survival (PFS)
Relapse [6 Months]
Cumulative Incidence of Relapse
Relapse [1 Year]
Cumulative Incidence of Relapse
Complete Remission (CR) [6 Months]
Rate of Complete Remission (CR)
Complete Remission (CR) [1 Year]
Rate of Complete Remission (CR)
Non-Relapse Mortality (NRM) [6 Months]
Cumulative Incidence of Non-Relapse Mortality (NRM)
Non-Relapse Mortality (NRM) [1 Year]
Cumulative Incidence of Non-Relapse Mortality (NRM)
Best Response [1 Year]
Best response until next line of treatment, death, or last follow up, whichever occurs sooner

Eligibility Criteria

Criteria

Ages Eligible for Study:

12 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Patient Inclusion Criteria:

Age ≥12 years
Have undergone first allo-HCT from a 6/6 matched sibling donor, 8/8 matched unrelated donor, or an HLA haploidentical donor.
History of AML or MDS for which allo-HCT was performed. Overlap MPN/MDS is included.
Untreated relapse of the underlying malignancy as defined by >5% of malignant blasts (by morphology and/or flow cytometry) in the bone marrow, or myeloid sarcoma.
Additional cells sufficient for the first DLI available from the same donor, or the donor must be willing to donate. Both G-CSF mobilized and unmobilized products are allowed and the choice is at the discretion of the treating physician.
Partial (or better) engraftment from the bone marrow showing relapse, defined as >50% donor chimerism on non-split RFLP. Patients with chimerism of 25-50% may be enrolled with approval of the site PI and Sponsor/Investigator
Karnofsky performance status ≥ 50%
Adequate organ function within 14 days of study registration defined as:
Total bilirubin < 1.5 x upper limit of institutional normal, unless a diagnosis of Gilbert's disease
AST/ALT < 2.5 x upper limit of institutional normal
Creatinine clearance ≥40 mL/minute as calculated by the Cockcroft-Gault formula. Cockcroft-Gault CrCl = (140-age) * (Wt in kg) * (0.85 if female) / (72 * Cr).
Peripheral white blood cell count <50 x 10^9/L. The use of hydroxyurea for cytoreduction is allowed and may continue until cycle 2 day 1
Subjects and spouse/partner who are of childbearing potential must be using highly effective contraception consisting of 2 forms of birth control (at least 1 of which must be a barrier method) starting at Screening and continuing through the entire study (for at least 3 months after the last dose of ruxolitinib if study treatment is stopped early or subject withdraws consent). Highly effective contraception is defined as:
Established use of oral, injected or implanted hormonal methods of contraception.
Placement of an intrauterine device or intrauterine system.
Double barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository (double barrier method will count as 2 forms of contraception).
Male subjects must not donate sperm during the Screening and Treatment Periods, and for at least 3 months after the last dose of ruxolitinib.
Subjects are willing and able to give written informed consent and to comply with all study visits and procedures. Parents or legal guardians will consent for minors and minors will be asked to assent.

Patient Exclusion Criteria:

Active uncontrolled infection at the time of consent. An active uncontrolled infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without signs or symptoms of infection will not be interpreted as an active uncontrolled infection. Subjects with a controlled infection receiving definitive therapy for 72 hours prior to enrollment are eligible.
History of infection with human immunodeficiency virus (HIV), unresolved hepatitis B, or hepatitis C.
Untreated CNS leukemia
Untreated or active GVHD (acute or chronic)
History of grade III-IV acute GVHD at any point in time
Any form of iatrogenic immunosuppression except <0.5 mg/kg/day of prednisone or equivalent at the time of consent.
Unresolved veno-occlusive disease of the liver, defined as persistent bilirubin abnormalities not attributable to GVHD and ongoing organ dysfunction (renal, ascites).
Subjects who are pregnant, breast feeding or sexually active and unwilling to use effective birth control for the duration of the study, as agents in this study are in pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, and category D: there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans.
Radiation therapy within 14 days prior to consent.
Any prior therapy for relapse after allo-HCT.
Prior DLI. CD34-selected boost is allowed
Exposure to any other investigational agent, device or procedure within 14 days prior to consent
Patients or donors with any medical or psychological condition that, in the opinion of the Investigator, might interfere with the subject's participation in the trial, pose any additional risk for the patient/donor, or confounds the assessments of the subject.
Subjects with known allergies, hypersensitivity or intolerance to ruxolitinib or similar compounds.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Masonic Cancer Center, University of Minnesota	Minneapolis	Minnesota	United States	55455
2	Washington University Medical School	Saint Louis	Missouri	United States	63130
3	University of Rochester Medical Center	Rochester	New York	United States	14642

Sponsors and Collaborators

Masonic Cancer Center, University of Minnesota
Incyte Corporation

Investigators

Principal Investigator: Armin Rashidi, MD, PhD, Division of Hematology, Oncology and Transplantation, University of Minnesota
Principal Investigator: Mark A Schroeder, M.D., Washington University School of Medicine
Principal Investigator: John F Dipersio, M.D., Ph.D., Washington University School of Medicine
Principal Investigator: Eric Huselton, M.D., University of Rochester